Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $45.00 and last traded at $45.0750, with a volume of 36102 shares. The stock had previously closed at $43.97.

Wall Street Analyst Weigh In

DNTH has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, October 8th. Guggenheim lifted their price objective on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. Stifel Nicolaus increased their target price on Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a report on Friday, September 12th. HC Wainwright raised their target price on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Raymond James Financial reissued an “outperform” rating and set a $63.00 price target (up from $56.00) on shares of Dianthus Therapeutics in a research report on Tuesday, September 9th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $63.43.

Dianthus Therapeutics Price Performance

The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -12.98 and a beta of 1.56. The business has a fifty day moving average of $37.38 and a 200 day moving average of $27.68.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.58 million. On average, analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Simrat Randhawa sold 109,031 shares of the company’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $152,560. This represents a 96.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The SEC filing for this sale provides additional information. Insiders have sold 216,538 shares of company stock worth $8,079,575 over the last three months. Company insiders own 8.15% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Large investors have recently added to or reduced their stakes in the stock. US Bancorp DE raised its position in shares of Dianthus Therapeutics by 2,013.3% in the first quarter. US Bancorp DE now owns 1,585 shares of the company’s stock valued at $29,000 after purchasing an additional 1,510 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Dianthus Therapeutics by 0.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company’s stock valued at $3,049,000 after buying an additional 1,081 shares during the last quarter. Invesco Ltd. raised its holdings in Dianthus Therapeutics by 38.7% in the 1st quarter. Invesco Ltd. now owns 15,978 shares of the company’s stock worth $290,000 after acquiring an additional 4,457 shares during the period. Nuveen LLC bought a new position in Dianthus Therapeutics in the 1st quarter worth $1,168,000. Finally, American Century Companies Inc. lifted its position in Dianthus Therapeutics by 8.7% during the 1st quarter. American Century Companies Inc. now owns 47,817 shares of the company’s stock worth $867,000 after acquiring an additional 3,821 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.